Shujing Liu

机构：First Affiliated Hospital of Zhengzhou University, University of Pennsylvania · ORCID：0000-0002-2958-093X

发表论文 97 篇 · 总被引 7706 次 · h-index 35

代表论文

• A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma (2019 · Nature Medicine · 被引 717)
• Ganoderma: A Cancer Immunotherapy Review (2018 · Frontiers in Pharmacology · 被引 102)
• Patient-derived melanoma organoid models facilitate the assessment of immunotherapies (2023 · EBioMedicine · 被引 96)
• ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma (2018 · Cancer Discovery · 被引 94)
• HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors (2022 · Nature Communications · 被引 86)
• PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma (2020 · JCI Insight · 被引 82)